The estimated Net Worth of Kenneth B Jr Lee is at least $537 Tisíc dollars as of 31 January 2023. Mr. Lee owns over 15,000 units of Biocryst Pharmaceuticals stock worth over $402,872 and over the last 13 years he sold BCRX stock worth over $0. In addition, he makes $134,088 as Independent Director at Biocryst Pharmaceuticals.
Sign up
Mr. Lee BCRX stock SEC Form 4 insiders trading
Kenneth has made over 9 trades of the Biocryst Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of BCRX stock worth $25,650 on 31 January 2023.
The largest trade he's ever made was exercising 22,917 units of Biocryst Pharmaceuticals stock on 6 March 2014 worth over $87,085. On average, Kenneth trades about 2,697 units every 108 days since 2011. As of 31 January 2023 he still owns at least 52,118 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Mr. Lee stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kenneth Lee biography
Kenneth B. Lee Jr. serves as Independent Director of the Company. Mr. Lee was appointed to the Board in June 2011. Mr. Lee has over 40 years of experience counseling management teams, boards of directors and investors of technology-based companies worldwide. He is currently a General Partner with Hatteras Venture Partners, LLC, a venture capital fund focusing on life science companies, which he joined in 2003. Previously he was President of A.M. Pappas & Associates, LLC, following 29 years with Ernst & Young LLP, where he was most recently Managing Director of the firm’s health sciences corporate finance group, and at one time served as the National Director of the Life Sciences Practice. Mr. Lee received a Bachelor of Arts degree from Lenoir-Rhyne College and an MBA from the University of North Carolina at Chapel Hill. Mr. Lee is currently on the Board of Directors of Aralez, Inc., and previously served on the Boards of private companies, Clinipace, Clinverse and A.M. Pappas & Associates. Previously, Mr. Lee served on the Boards of Abgenix, Inc., CV Therapeutics, Inspire Pharmaceuticals, Maxygen, Inc., and OSI Pharmaceuticals. He has served in various leadership capacities on these Boards, including Chairman of the Board, Independent Lead Director and Chairman of Audit and Compensation Committees. Mr. Lee’s experience advising biotechnology companies regarding financial and partnering strategies, his extensive background in finance and his experience serving on the Boards of biotech companies contribute valuable insight and experience to the Board.
What is the salary of Kenneth Lee?
As the Independent Director of Biocryst Pharmaceuticals, the total compensation of Kenneth Lee at Biocryst Pharmaceuticals is $134,088. There are 10 executives at Biocryst Pharmaceuticals getting paid more, with Jon Stonehouse having the highest compensation of $2,284,300.
How old is Kenneth Lee?
Kenneth Lee is 72, he's been the Independent Director of Biocryst Pharmaceuticals since 2011. There are 1 older and 21 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.
What's Kenneth Lee's mailing address?
Kenneth's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, , DURHAM, NC, 27703.
Insiders trading at Biocryst Pharmaceuticals
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... a Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
What does Biocryst Pharmaceuticals do?
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
What does Biocryst Pharmaceuticals's logo look like?
Complete history of Mr. Lee stock trades at Biocryst Pharmaceuticals a Eyenovia Inc
Biocryst Pharmaceuticals executives and stock owners
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Jon Stonehouse,
President, Chief Executive Officer, Director -
Megan Sniecinski,
Senior Vice President, Chief Business Officer -
Alane Barnes,
Senior Vice President, Chief Legal Officer and Corporate Secretary -
Jon P. Stonehouse,
CEO, Pres & Exec. Director -
Yarlagadda Babu,
Senior Vice President - Drug Discovery -
William Sheridan,
Senior Vice President, Chief Medical Officer -
Dr. William P. Sheridan,
Chief Medical Officer & Sr. VP -
Dr. Yarlagadda S. Babu,
Chief Discovery Officer -
Stephen Aselage,
Independent Director -
Robert Ingram,
Independent Chairman of the Board -
Kenneth Lee,
Independent Director -
Nancy Hutson,
Independent Director -
George Abercrombie,
Independent Director -
Theresa Heggie,
Independent Director -
Helen Thackray,
Independent Director -
Dr. Helen M. Thackray FAAP, M.D.,
Chief R&D Officer -
Anthony Doyle,
Chief Financial Officer, Senior Vice President -
Alan Levin,
Independent Director -
Charles Gayer,
Senior Vice President, Chief Commercial Officer -
Allen Hodge,
Vice President and General Manager for the United States -
Michael Jones,
Executive Director - Finance, Principal Accounting Officer -
Alane P. Barnes,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Michael L. Jones,
Exec. Director of Fin. & Principal Accounting Officer -
Dr. Elliott T. Berger,
Sr. VP of Regulatory Affairs -
Robert C. Stoner,
VP of HR -
John D. Bluth,
Sr. VP of Investor Relations & Corp. Communications -
Anthony Doyle,
Sr. VP & CFO -
Sanj K Patel,
Director -
Stanley C Erck,
Director -
Fred E Cohen,
Director -
Lynne Powell,
Senior VP - CCO -
Thomas R Ii Staab,
Senior Vice President and CFO -
Bros. Advisors Lp Baker Bro...,
-
John L Higgins,
Director -
Felix Baker Bros. Investmen...,
-
Zola P Horovitz,
Director -
Robert S Lowrey,
Controller, PAO -
Steven K Galson,
Director -
Steve Aselage,
Director -
Brothers Life Sciences Capi...,
-
David Mc Cullough,
VP -
Bros. Capital (Gp), Llcbake...,
-
Stephen R Biggar,
Director -
Stuart Grant,
SR VP & CFO -
Beth C Seidenberg,
Director -
William W Featheringill,
Director -
/ Tisch Capital (Gp), Llcba...,
-
Biotech Capital (Gp), Llcba...,
-
Capital (Gp), Llcbaker Juli...,
-
Mike Mills,
Principal Accounting Officer -
Partners L P/Ilbiotechnolog...,
-
Carl L Gordon,
Director -
Charles E Bugg,
CEO -
J Claude Bennett,
President -
John A Montgomery,
Director -
Jonathan M Nugent,
VP Corp Communications -
W James Alexander,
SR. VP, Chief Medical Officer -
Randall B Riggs,
VP Business Development -
Michael A Darwin,
CFO -
Randolph C Steer,
Director -
Joseph H Jr Sherrill,
Director -
William M Iii Spencer,
Director -
Charles A Sanders,
Director -
Peder Jensen,
Director -
Amy E Mc Kee,
Director -
Machelle Sanders,
Director -
Vincent Milano,
Director